Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark
A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.
Asset / Drug
Drug and asset intelligence for Acelity with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Stem Cell Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.